Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands

NCT04626271 | Completed Results FDA Device

• 1 other identifier: ACR-US-MCU-01
• Study Type: interventional
• Target: 250
• Locations: 1 country
• Sites: 2

Brief Summary

Eligible subjects meeting the pathological profile will be recruited at the designated site by the study personnel. Following subject consent, the subjects will be evaluated for eligibility based on their health condition and history. The ACR \| U.S. kit, in its original packaging, along with the ACR \| U.S. smartphone application will be provided to the subject in a simulated home- use environment. All subjects will be provided with a list of tasks to complete, including providing a urine sample and operating the ACR \| U.S. device on 2 mobile phones. After completing the test, the lay user will complete a post-test questionnaire. The study observer will also complete a questionnaire to collect information regarding the lay users' use of the ACR \| U.S. The device use will be compared with identified risks to determine if the percentage of failures is acceptable. Additionally, measurable usability criteria for specific, critical steps will be evaluated. Following the usability test performed by the lay user, the subjects' urine samples will be tested by the study staff using the comparator device. These results will be considered as the "true value".

Conditions

Albuminuria

Outcome Measures

Primary Outcomes (1)

• Accuracy Evaluation: The Degree of Agreement (%) of the ACR | U.S. Urine Analysis Test System as Compared to the Comparator Device

  The primary objective of the study is to evaluate the % exact match (percent agreement) and the % ±1 block match (percent agreement) of ACR \| U.S. Urine Analysis Test System (tested by the lay user) compared to the URiSCAN Optima Urine Analyzer (the comparator device, tested by a healthcare professional user), for all reported values (blocks). Different concentrations reported by the ACR \| U.S. Urine Analysis Test System were compared with results from the comparator device.

  2 months

Secondary Outcomes (1)

• Usability Evaluation: User Performance Analysis

  2 months

Study Arms (1)

ACR | U.S. Urine Analysis Test System

EXPERIMENTAL

Urine samples are collected and tested by a lay user, using the new home use device. The lay user test results are compared to the results obtained by testing the same urine sample on the comparison device.

Device: ACR | U.S. Urine Analysis Test System; Device: URiSCAN Optima Urine Analyzer

Interventions

ACR | U.S. Urine Analysis Test System DEVICE

Each study participant will test their urine sample using the ACR \| U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health.

ACR | U.S. Urine Analysis Test System

URiSCAN Optima Urine Analyzer DEVICE

Upon completion of the test using the ACR \| U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer.

ACR | U.S. Urine Analysis Test System

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and Females 18-80 years of age.
• Subjects diagnosed with a disease that normally represents itself with an abnormal concentration of albumin:
• Diabetes Type I/Type II,
• Hypertension,
• any kidney disease,
• other relevant conditions,
• or, subjects who are healthy or pregnant.
• Subject is familiar with the use of a smartphone.
• Subject is capable of comprehending and following instructions in English.
• Subject has facility with both hands.
• Subject is capable and willing to adhere to the study procedures.
• Subject is capable and willing to provide informed consent.

You may not qualify if:

• Subject has dementia.
• Subject has severe mental disorders.
• Subject cannot collect urine in a receptacle.
• Subject is visually impaired (cannot read the user manual).
• Any additional reason the study physician believes disqualifies the subject from participating in the study.

Sponsors & Collaborators

• Healthy.io Ltd.: lead

Study Sites (2)

AccuMed research associates

Garden City, New York, 11530, United States

Location

PMG Research of Charleston

Charleston, South Carolina, 29464, United States

Location

MeSH Terms

Conditions

Albuminuria

Condition Hierarchy (Ancestors)

Proteinuria; Urination Disorders; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Dr. Danielle Jeddah (Director of Clinical Development) OR Jennifer Kachel Acobas (Director of RA)
• Organization: Healthy.io

danielle.jeddah@healthy.io, jennifer.acobas@healthy.io

0543111050, 0528345562

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 25, 2020
• First Posted: November 12, 2020
• Study Start: August 31, 2020
• Primary Completion: October 23, 2020
• Study Completion: October 25, 2020
• Last Updated: May 9, 2023
• Results First Posted: May 9, 2023

Record last verified: 2023-04

Locations

US (2)